12,828 Shares in USANA Health Sciences, Inc. $USNA Bought by Walleye Capital LLC

Key Points

• Walleye Capital LLC has acquired a new position in USANA Health Sciences, purchasing 12,828 shares valued at approximately $346,000, representing around 0.07% of the company's stock.
• USANA Health Sciences received an upgrade from "hold" to "buy" by Wall Street Zen, with two analysts currently rating the stock as a hold, and an average price target of $36.00.
• The company reported a Q2 EPS of $0.74, exceeding analysts' expectations of $0.54, and had a revenue of $235.85 million for the quarter, surpassing the consensus estimate.

Walleye Capital LLC bought a new stake in USANA Health Sciences, Inc. (NYSE:USNA - Free Report) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 12,828 shares of the company's stock, valued at approximately $346,000. Walleye Capital LLC owned 0.07% of USANA Health Sciences at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. PNC Financial Services Group Inc. lifted its stake in shares of USANA Health Sciences by 339.6% in the 1st quarter. PNC Financial Services Group Inc. now owns 998 shares of the company's stock valued at $27,000 after purchasing an additional 771 shares during the period. Versant Capital Management Inc grew its stake in shares of USANA Health Sciences by 542.5% in the first quarter. Versant Capital Management Inc now owns 1,150 shares of the company's stock worth $31,000 after purchasing an additional 971 shares during the last quarter. Parallel Advisors LLC lifted its holdings in shares of USANA Health Sciences by 8,141.2% during the first quarter. Parallel Advisors LLC now owns 1,401 shares of the company's stock valued at $38,000 after purchasing an additional 1,384 shares during the last quarter. AlphaQuest LLC grew its position in USANA Health Sciences by 300.9% in the 1st quarter. AlphaQuest LLC now owns 3,412 shares of the company's stock worth $92,000 after purchasing an additional 2,561 shares during the period. Finally, US Bancorp DE boosted its holdings in USANA Health Sciences by 13.1% in the 1st quarter. US Bancorp DE now owns 4,611 shares of the company's stock worth $124,000 after buying an additional 535 shares during the period. 54.25% of the stock is owned by institutional investors and hedge funds.

USANA Health Sciences Trading Down 2.2%

Shares of USANA Health Sciences stock traded down $0.72 on Monday, reaching $31.11. 47,252 shares of the stock were exchanged, compared to its average volume of 172,049. USANA Health Sciences, Inc. has a 1-year low of $23.10 and a 1-year high of $41.83. The business has a fifty day moving average price of $31.24 and a two-hundred day moving average price of $29.57. The firm has a market capitalization of $568.29 million, a PE ratio of 17.29, a PEG ratio of 1.01 and a beta of 0.64.

USANA Health Sciences (NYSE:USNA - Get Free Report) last announced its quarterly earnings results on Tuesday, July 22nd. The company reported $0.74 earnings per share for the quarter, beating analysts' consensus estimates of $0.54 by $0.20. USANA Health Sciences had a net margin of 3.79% and a return on equity of 9.48%. The company had revenue of $235.85 million for the quarter, compared to analyst estimates of $225.20 million. USANA Health Sciences has set its FY 2025 guidance at 2.350-3.000 EPS. Research analysts expect that USANA Health Sciences, Inc. will post 2.45 EPS for the current year.

Analyst Ratings Changes

Separately, Wall Street Zen raised shares of USANA Health Sciences from a "hold" rating to a "buy" rating in a report on Thursday, May 22nd. Two equities research analysts have rated the stock with a Hold rating, According to data from MarketBeat, the stock has an average rating of "Hold" and an average target price of $36.00.

Insider Buying and Selling at USANA Health Sciences

In other news, insider David Mulham Mulham sold 3,515 shares of the firm's stock in a transaction dated Wednesday, July 30th. The shares were sold at an average price of $30.26, for a total transaction of $106,363.90. Following the completion of the transaction, the insider directly owned 9,260 shares of the company's stock, valued at approximately $280,207.60. This trade represents a 27.51% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Gilbert A. Fuller sold 1,058 shares of the business's stock in a transaction that occurred on Thursday, August 7th. The stock was sold at an average price of $29.10, for a total transaction of $30,787.80. The disclosure for this sale can be found here. Company insiders own 0.63% of the company's stock.

About USANA Health Sciences

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.